Global In Vivo CRO Market Grows Steadily at a CAGR of 8.2%

Introduction

A specialized company known as In Vivo CRO (Contract Research Organization) specializes in supervising studies and trials involving living organisms. Due to the complexity and regulatory requirements of the pharmaceutical and biotechnology industries, CRO is essential to the development of new medications and remedies.

In vivo CRO companies design and conduct preclinical and clinical studies that employ animal models to evaluate new drug candidates' pharmacokinetics, efficacy, and safety. They collaborate closely with pharmaceutical companies, academic institutions, and government agencies to ensure compliance with ethical and legal standards. These institutes are equipped with cutting-edge technology and are knowledgeable in toxicology, pharmacology, and veterinary sciences. The In Vivo CRO offers many services, including protocol development, subject recruitment, data collection, analysis, and reporting. They collaborate with seasoned researchers, veterinarians, and support personnel who adhere to stringent quality control standards and are trained in animal care.

Market Dynamics

Rising Price Competition and Requirement to Reduce Cost Drive the Global Market

The maturation of the in vivo industry as a market is a factor that positively influences market expansion. Intense competition, price increases, and profitability pressure are additional factors. Every country on earth is experiencing a progressive increase in industry competition. Emerging nations such as Brazil, Korea, Taiwan, and China are becoming increasingly formidable competitors on the international stage.

While pharmaceutical and biotech companies based in the Netherlands, Germany, Bermuda, and Japan compete fiercely with U.S. firms, these nations also confront fierce competition from emerging economies. Due to expanding challenges and shifting market dynamics, numerous pharmaceutical and biotech companies have adopted an outsourcing business model to reduce costs and better manage operational risks.

Complex Cell and Gene Therapies Require Innovative Clinical Trial Designs Creates Tremendous Opportunities

The complexity of gene and cell therapies necessitates extensive specialized training. It is believed that they satisfy unmet needs in the medical industry. As a result, investments in developing and commercializing innovative cell and gene therapies have increased. The FDA has approved sixteen cell and gene therapies as of April 2021. Approximately 362 cell and gene therapies will have reached the clinical trial stage by 2020. Due to the rapidly increasing number of potential cell therapy candidates and their rapid progression through the various phases of clinical development, there has been an increase in demand for institutions that offer research and development services for these therapies. Due to this, end-users like biotech companies and academic institutions have decided to rely on CROS for their specialized knowledge and scientific comprehension.

In addition, CROS provides greater clarity regarding regulatory requirements and a wider geographical reach for clinical trials. As a result, these factors would propel the market for CRO services forward.

Regional Analysis

North America is the most significant global in vivo CRO market shareholder and is estimated to exhibit a CAGR of 8.5% over the forecast period. Due to the presence of technologically advanced Contract Research Organizations (CROs) and a growth in the number of funding granted by government organizations (such as the National Institute of Health (NIH) to stimulate research activities), North America leads the global market for in vivo CROs. It is anticipated that additional expenditures will be made in research throughout the projected period due to the high quality and track record of companies operating in the region. In addition, the numerous drug development activities, the presence of several pharmaceutical and biotech businesses, and the number of clinical trials in the region are contributing to the expansion of the market.

Asia-Pacific is anticipated to exhibit a CAGR of 9.4% over the forecast period. The cost-effectiveness of clinical research organizations (CROs) in countries such as India and China is anticipated to drive growth in the Asia Pacific region at the quickest compound annual growth rate (CAGR). This is in addition to the region's economic development and advanced healthcare infrastructure. The growing number of partnerships and investments made by CROs, as well as the growing percentage of in vivo services that are outsourced to emerging economies such as India and China, are two of the factors that are predicted to accelerate market expansion throughout the forecast period. Other factors predicted to accelerate market expansion throughout the forecast period include the growth of the global population.

 

Key Highlights

• The global in vivo CRO market size was valued at USD 4.23 billion in 2022. It is estimated to reach USD 8.6 billion by 2031, growing at a CAGR of 8.2% during the forecast period (2023–2031).
• Based on the type, the global in vivo CRO market is bifurcated into rodent and non-rodent. The Rodent segment dominates the global market and is predicted to exhibit a CAGR of 8.6% over the forecast period.
• Based on disease indication, the global in vivo CRO market is bifurcated into autoimmune/inflammation conditions, pain management, oncology, CNS conditions, diabetes, obesity, etc. The oncology segment owns the highest market share and is predicted to exhibit a CAGR of 8.2% over the forecast period.
• Based on GLP type, the global in vivo CRO market is divided into non-GLP and GLP toxicology. The GLP toxicology segment is the most significant contributor to the market and is estimated to exhibit a CAGR of 8.8% over the forecast period.
• North America is the most significant global in vivo CRO market shareholder and is estimated to exhibit a CAGR of 8.5% over the forecast period.

Competitive Players

Competitive Players

The key players in the global in vivo CRO market are IQVIA Inc., Crown Bioscience, Taconic Biosciences, Inc., Psychogenic Inc., Evotec, Janvier Labs, Biocytin, Gem Pharmatech, Charles River Laboratories, Icon Plc, LabCorp Drug Development, Parexel International Corporation, and SMO Clinical Research (I) Pvt Ltd.

 

Recent Developments

Market News

• In March 2023, ClinChoice Medical Development, a US-based contract research organization (CRO) that provides research services to accelerate drug and device approvals, acquired Cromsource S.r.l. for an undisclosed amount.
• In October 2022, Moderna, Inc., and Merck reported that Merck had exercised its option to develop and commercialize personalized cancer vaccine (PCV) jointly mRNA-4157/V940 under the terms of its existing Collaboration and License Agreement.

 

Segmentation

Global In Vivo CRO Market: Segmentation

By Type

• Rodent
• Non-Rodent

By Disease Indication 

• Autoimmune/inflammation conditions
• Pain management
• Oncology
• CNS conditions
• Diabetes
• Obesity
• Others

By GLP Type

• Non GLP
• GLP Toxicology

By Regions

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa